With the partnering of ceftobiprole in the US announced today, Basilea has delivered on its objectives to build a leading global anti-infectives company. Ceftobiprole and recently acquired fosmanogepix should now offset the impact of Cresemba's loss of exclusivity in the US and Europe at the end of 2027.
